BDNF and myeloid sarcoma: In the same year, her group also demonstrated that the brain-derived neurotrophic factor (BDNF) and its Val66Met polymorphism may represent a potential biomarker for susceptibility to and severity of CI in MS due to their protective role in cognitive dysfunction (De Meo et al., 2022).